Experimental infection with herpes simplex virus type 2 in newborn rats: Effects of treatment with iododeoxyuridine and cytosine arabinoside.

Sprague-Dawley rats were inoculated, within 36 hr of birth, with either of two strains of herpes simplex virus type 2. The effects of treatment for five days with either 5-iododeoxyuridine or cytosine arabinoside in near toxic doses were studied. Evaluation of treatment based on rate of survival, incidence of lesions, and isolation of virus from the central nervous system showed no appreciable difference between treated and untreated littermates. Drug-related effects of retardation of growth and defective development of the cerebellum and retina were found. The validity of therapy with either of these drugs in generalized herpetic infections is questioned because activity was minimal against the infecting agent even when the dosage of the drug was sufficient to produce serious defects in certain developing tissues.

[1]  D. Albert,et al.  Developmental defects in mice and rats treated postnatally with cytosine arabinoside. , 1974, Experimental and molecular pathology (Print).

[2]  D. Albert,et al.  Developmental defects in rats treated postnatally with 5-iododeoxyuridine (IUDR). , 1974, Teratology.

[3]  A. Friedman-kien,et al.  Herpes Simplex Virus Skin Infection in Hairless Mice: Treatment with Antiviral Compounds , 1974, Antimicrobial Agents and Chemotherapy.

[4]  C. Liu,et al.  Effects of idoxuridine on Herpesvirus hominis encephalitis and disseminated infections in marmosets. , 1973, The Journal of infectious diseases.

[5]  H. Renis,et al.  Antiviral Activity of Cytarabine in Herpesvirus–Infected Rats , 1973, Antimicrobial Agents and Chemotherapy.

[6]  J. B. Hanshaw.  Herpesvirus hominis infections in the fetus and the newborn. , 1973, American journal of diseases of children.

[7]  B. Roizman,et al.  Infection with herpes-simplex viruses 1 and 2. II. , 1973, The New England journal of medicine.

[8]  E. Kern,et al.  Herpesvirus hominis infection in newborn mice. I. An experimental model and therapy with iododeoxyuridine. , 1973, The Journal of infectious diseases.

[9]  A. Chow,et al.  Cytosine Arabinoside Therapy for Herpes Simplex Encephalitis—Clinical Experience with Six Patients , 1973, Antimicrobial Agents and Chemotherapy.

[10]  F. Rapp,et al.  The effect of cytosine arabinoside on virus production in various cells infected with herpes simplex virus types 1 and 2. , 1973, Cancer research.

[11]  A. Lerner,et al.  Concentrations of idoxuridine in serum, urine, and cerebrospinal fluid of patients with suspected diagnoses of Herpesvirus hominis encephalitis. , 1972, The Journal of clinical investigation.

[12]  J. Bellanti,et al.  Herpes simplex encephalitis: brain biopsy and treatment with 5-iodo-2'-deoxyuridine. , 1968, The Journal of pediatrics.

[13]  S. Tanaka,et al.  Zoster-Like Lesions from Herpes Simplex Virus in Newborn Rats.∗ , 1965, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[14]  P. Calabresi.  CURRENT STATUS OF CLINICAL INVESTIGATIONS WITH 6-AZAURIDINE, 5-IODO-2'-DEOXYURIDINE, AND RELATED DERIVATIVES. , 1963, Cancer research.